As a result of pro-active monitoring for foetal defects following maternal drug exposure to sumatriptan, the IMMP has records of outcomes in 26 pregnancies from 31 pregnancy exposures. This compares with 223 pregnancy outcomes in the international sumatriptan pregnancy registry managed by GlaxoWellcome (Eldridge and Ephross, 1999). There is no evidence that suma-triptan causes foetal defects. There are also 30 reports of outcome following lactation exposure. Again there is no evidence of a problem.
Was this article helpful?